NOVMETAPHARMA CO., LTD
14Patents
14Active
14Granted
47Portfolio score
Filing activity: Feb 16, 2016 → Jul 1, 2022
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10792280B2 | Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes | Human Necessities | 3 | Active |
| US10683300B2 | Polymorphic forms of Cyclo (-His-Pro) | Chemistry; Metallurgy | 2 | Active |
| US10918693B2 | Composition for cell protection containing cyclo histidine-proline as active ingredient | Human Necessities | 2 | Active |
| US11433114B2 | Composition for cell protection containing cyclo histidine-proline as active ingredient | Human Necessities | 1 | Active |
| US11890317B2 | Cell-protecting composition containing cyclo histidine-proline as active ingredient | Human Necessities | 0 | Active |
| US11975041B2 | Composition comprising CHP (cyclo-his pro) for preventing, improving or treating of bone loss related disease | Human Necessities | 0 | Active |
| US11607441B2 | Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients | Human Necessities | 0 | Active |
| US11820834B2 | Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease | Human Necessities | 0 | Active |
| US11547737B2 | Compositions and methods for treating virus infection | Emerging Cross-Sectional Technologies | 0 | Active |
| US10004727B2 | Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient | Human Necessities | 0 | Active |
| US11413270B2 | Method for the treatment of pancreatitis | Human Necessities | 0 | Active |
| US11273196B2 | Antithrombotic composition containing Polygonum cuspidatum sieb. et zucc. and Cinnamomum cassia blume | Human Necessities | 0 | Active |
| US12053467B2 | Method of treating fibrosis | Human Necessities | 0 | Active |
| US11850246B2 | Method for treatment of cytokine release syndrome | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.